Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$127.90

1 (0.79%)

, CELG

Celgene

$142.07

1.15 (0.82%)

08:01
09/13/17
09/13
08:01
09/13/17
08:01

bluebird bio announces first patient treated in expansion cohort of CRB-401

bluebird bio (BLUE) announced that the expansion cohort of the CRB-401 Phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated. The objective of the CRB-401 study is to evaluate the safety and efficacy of bb2121 in patients with relapsed/refractory multiple myeloma and determine a recommended Phase 2 dose. bluebird bio and Celgene (CELG) are jointly developing bb2121. Patients in the expansion cohort will be treated at a dose range of 150 to 450 x 106 CAR+ T cells and will be required to have prior exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.

BLUE

bluebird bio

$127.90

1 (0.79%)

CELG

Celgene

$142.07

1.15 (0.82%)

  • 13

    Sep

  • 14

    Sep

  • 25

    Sep

  • 27

    Sep

BLUE bluebird bio
$127.90

1 (0.79%)

08/29/17
MAXM
08/29/17
NO CHANGE
Target $18
MAXM
Buy
Maxim wonders if Cellular Biomedicine is next target after Kite
In a research note titled "When the Music Stop's who will be Left? In the Wake of Gilead's Planned Acquisition of Kite, Could CBMG be Next?," Maxim analyst Gabrielle Zhou calls Cellular Biomedicine (CBMG) a "potential undiscovered gem" in the CAR-T landscape. As the market shifts focus to the remaining standalone CAR-T players like Juno Therapeutics (JUNO) and bluebird bio (BLUE) following Gilead Sciences' (GILD) acquisition of Kite Pharma (KITE), Cellular Biomedicine offers an opportunity in China, Zhou tells investors. The analyst is looking forward to data from both the company's CARD-1 and CALL-1 CAR-T studies by the end of 2017. Zhou has a Buy rating on the shares with an $18 price target. Cellular in midday trading is down 5c to $8.95.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Equal Weight
Gilead response to Kymriah pricing 'confusing,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said Novartis' (NVS) pricing of its Kymriah therapy at $475,000 gross puts "some slight pressure" on his model for Juno Therapeutics (JUNO), though he doesn't see it as "that far out of line" with his expectations. While he said it makes sense that Juno saw some pressure yesterday after the pricing news and that bluebird bio (BLUE) closed the gap with Juno, he called Gilead's (GILD) strength yesterday "a bit more confounding" given that Gilead is focused on the same indication as Juno. However, initial DLBCL sales in 2018 for both Gilead and Novartis are likely to drive sentiment, so greater clarity won't be seen until then, added Harrison, who keeps an Equal Weight rating on Juno shares.
08/31/17
BMOC
08/31/17
NO CHANGE
BMOC
bluebird bio price target raised to $134 from $108 at BMO Capital
BMO Capital analyst Matthew Luchini increased his price target on bluebird (BLUE) after the FDA approved Novartis' (NVS) CAR-T treatment for the treatment of pediatric ALL. The analyst thinks that the approval lowers the risk facing all CAR-T companies. He now sees a 60% chance of approval for bluebird's CAR-T treatment, bb2121, up from 45% previously, and he raised his estimate of the price of the treatment to $300,000 from $225,000 based on the $475,000 price of Novartis' treatment. He keeps an Outperform rating on the shares.
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
bluebird bio initiated with an Overweight at Barclays
Barclays initiated bluebird bio with an Overweight and a $151 price target, citing the company's strategic focus on diseases curable with hematopoietic stem cell transplants, and "impressive" efficacy/safety data for bb2121.
CELG Celgene
$142.07

1.15 (0.82%)

09/07/17
LEER
09/07/17
NO CHANGE
LEER
Alexion, Celgene top picks at Leerink
Leerink analyst Geoffrey Porges notes large cap biotech stocks have performed strongly this year and have reversed some of the wide discount they were carrying compared to their history and to other medical products sectors. Further, he points out consensus revenue and earnings estimates for biotech companies have started to trend positively, after negative revisions earlier in the year. Porges still sees significant upside for many of the names in his coverage, and he anticipates that further appreciation can occur on the basis of recovering sentiment and multiples, further estimate revisions toward his current models, and confirmation of option value for unpriced pipeline opportunities. The analyst top picks are now Alexion (ALXN), Celgene (CELG), Regeneron (REGN), and Vertex (VRTX). Among his Market Perform rated stocks, his preference would be for AbbVie (ABBV).
09/08/17
ADAM
09/08/17
NO CHANGE
Target $156
ADAM
Buy
FDA FUSION program hold of minimal concern for Celgene, says Canaccord
Canaccord analyst John Newman noted the FDA put a partial hold on five trials and a full hold on one trial in the FUSION program, but said it should have minimal impact on Celgene fundamentals. The analyst still sees year-end approval for ozanimod and continued Revlimed revenue growth to support its valuation. Newman maintained his Buy rating and $156 price target on Celgene shares.
09/08/17
FBCO
09/08/17
NO CHANGE
Target $156
FBCO
Outperform
Celgene trial holds more class-wide than durvalumab-specific, says Credit Suisse
Credit Suisse analyst Alethia Young does not think the clinical holds placed by the FDA on Celgene's (CELG) PD1 trials for durvalumab have anything to do with the safety issue of the trials, but are more of a class-wide review taken after the hold on Merck's (MRK) Keytruda, she tells investors in a research note. Celgene said it has not seen a risk/benefit imbalance in the over 500 patients treated in the FUSION program, she added. Young, who currently doesn't include durvalumab in her valuation of Celgene, keeps an Outperform rating and $156 price target on the stock.
09/11/17
MAXM
09/11/17
NO CHANGE
MAXM
BeiGene data, Celgene deal closing positive, says Maxim
Maxim analyst Gabrielle Zhou says that preliminary data on a Phase 1/II trial of BeiGene's (BGNE) BGB-290 in patients with advanced solid tumors, including epithelial ovarian cancer, or EOC, showed that the drug has "a similar, if not superior anti-tumor effect compared to other PARP inhibitors in patients with EOC and other solid tumors." Zhou adds that the closing of the company's deal with Celgene (CELG) is also positive. The analyst raised her price target on BeiGene to $77 from $73 and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46
Syndicate
Iovance Biotherapeutics 7.69M share Secondary priced at $6.50 »

The deal priced at $6.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 21

    Sep

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

18:28
09/20/17
09/20
18:28
09/20/17
18:28
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$86.37

-3.55 (-3.95%)

, TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
Sandisk subsidiaries initiate new arbitration proceedings against Toshiba »

Western Digital (WDC)…

WDC

Western Digital

$86.37

-3.55 (-3.95%)

TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

TOSBF

Toshiba, also use TOSYY

$2.87

-0.02 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOA

North American Energy

$4.10

-0.05 (-1.20%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
North American Energy awarded two earthworks contracts for $90M »

North American Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$23.15

0.15 (0.65%)

18:01
09/20/17
09/20
18:01
09/20/17
18:01
Hot Stocks
Investar Holding raises quarterly dividend to 3c from 2c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$47.86

-0.63 (-1.30%)

17:56
09/20/17
09/20
17:56
09/20/17
17:56
Syndicate
Beacon Roofing 6.325M share Secondary priced at $47.50 »

BofA/Merrill, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

AMD

AMD

$13.74

0.62 (4.73%)

, AMPH

Amphastar

$15.64

-0.02 (-0.13%)

17:46
09/20/17
09/20
17:46
09/20/17
17:46
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: AMD (AMD), up 6%…

AMD

AMD

$13.74

0.62 (4.73%)

AMPH

Amphastar

$15.64

-0.02 (-0.13%)

GVP

GSE Systems

$2.80

0.05 (1.82%)

MLHR

Herman Miller

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 28

    Sep

ABMD

Abiomed

$157.42

0.32 (0.20%)

17:36
09/20/17
09/20
17:36
09/20/17
17:36
Hot Stocks
Abiomed receives FDA PMA approval for Impella RP for right heart failure »

Abiomed has received FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSK

Oshkosh

$79.69

0.34 (0.43%)

17:35
09/20/17
09/20
17:35
09/20/17
17:35
Hot Stocks
Oshkosh awarded $466.7M government contract modification »

Oshkosh Defense, Oshkosh,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$155.03

-1.01 (-0.65%)

17:32
09/20/17
09/20
17:32
09/20/17
17:32
Hot Stocks
Aetna president Lynch sells $2.5M of company shares »

The president of health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$5.22

-0.29 (-5.26%)

17:25
09/20/17
09/20
17:25
09/20/17
17:25
Hot Stocks
Blue Apron jumps after meal kit competitor Plated acquired by Albertsons »

Earlier today, food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Earnings
Dr Pepper Snapple cuts FY17 EPS view to $4.53-$4.63 from $4.56-$4.66 »

FY17 consensus $4.63. In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$24.64

-0.07 (-0.28%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Downgrade
Hanesbrands rating change at Nomura Instinet »

Hanesbrands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

, SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

17:19
09/20/17
09/20
17:19
09/20/17
17:19
Hot Stocks
Breaking Hot Stocks news story on Third Point Reinsurance, Sanderson Farms »

Third Point Reinsurance…

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

17:18
09/20/17
09/20
17:18
09/20/17
17:18
Hot Stocks
Sanderson Farms to replace Cabela's in S&P 400 at open on 9/26 »

Bass Pro Shops is…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:14
09/20/17
09/20
17:14
09/20/17
17:14
Hot Stocks
Intellipharmaceutics receives Nasdaq non-compliance notice »

Intellipharmaceutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RWLK

ReWalk Robotics

17:13
09/20/17
09/20
17:13
09/20/17
17:13
Syndicate
Breaking Syndicate news story on ReWalk Robotics »

ReWalk Robotics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABM

ABM

$39.29

0.23 (0.59%)

17:11
09/20/17
09/20
17:11
09/20/17
17:11
Hot Stocks
Breaking Hot Stocks news story on ABM »

Thomas H. Lee Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$8.35

-0.15 (-1.76%)

17:07
09/20/17
09/20
17:07
09/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on Invuity »

Discovery Group raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

USG

USG

$31.26

1.84 (6.25%)

, CBPX

Continental Building

$25.60

1.25 (5.13%)

17:04
09/20/17
09/20
17:04
09/20/17
17:04
Hot Stocks
Gypsum stocks jump after peer National Gypsum announces price increase »

Shares of companies…

USG

USG

$31.26

1.84 (6.25%)

CBPX

Continental Building

$25.60

1.25 (5.13%)

EXP

Eagle Materials

$105.07

2.9 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

TRHC

Tabula Rasa HealthCare

$25.66

-0.38 (-1.46%)

16:46
09/20/17
09/20
16:46
09/20/17
16:46
Recommendations
Tabula Rasa HealthCare analyst commentary at Piper Jaffray »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:40
09/20/17
09/20
16:40
09/20/17
16:40
General news
Fed Leans into Wind on Balance Sheet: »

Fed Leans into Wind on…

TPIV

TapImmune

$3.08

-0.01 (-0.32%)

16:37
09/20/17
09/20
16:37
09/20/17
16:37
Syndicate
Breaking Syndicate news story on TapImmune »

TapImmune files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBSB

Meridian Bancorp

$18.15

0.1 (0.55%)

16:36
09/20/17
09/20
16:36
09/20/17
16:36
Hot Stocks
Meetinghouse receives shareholder approval for merger with Meridian Bancorp »

Meridian Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNY

Kearny Financial

$15.10

0.2 (1.34%)

16:34
09/20/17
09/20
16:34
09/20/17
16:34
Hot Stocks
Kearny Financial declares special cash dividend of 12c per share »

Kearny Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.